12:00 AM
 | 
Apr 19, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GI-5005: Additional Phase IIb data

Additional data from a Phase IIb trial in 140 patients with chronic HCV genotype 1 showed that significantly more patients receiving GI-5005 plus standard care with Copegus ribavirin and Pegasys peginterferon alfa-2a had undetectable HCV RNA vs. standard care alone (63% vs. 45%; p=0.037). GI-5005 plus standard care also...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >